Noxopharm (ASX: NOX) announces that it will apply its glutamate-inhibition technology to the treatment of glioblastoma multiforme (GBM).
SYDNEY, Australia, Oct. 18, 2019 (GLOBE NEWSWIRE) -- Noxopharm (ASX: NOX) announces that it will apply its glutamate-inhibition technology to the treatment of glioblastoma multiforme (GBM).
GBM remains a poorly managed cancer, with surgery, radiotherapy and the chemotherapy drug, temozolomide, the current standard of care, offering median survival of only 12-15 months.
Recent research now has confirmed that brain chemical, glutamate, is playing a key role in driving the aggressive nature of GBM growth.1,2
Glutamate is an important brain chemical, triggering passage of electrical impulses between brain cells. These chemicals are known as neurotransmitters. Glutamate is the brain’s main neurotransmitter, with important roles in learning and memory.
GBM cancer cells now have been shown to be connected to brain cells (neurons) that are feeding glutamate into the tumour, driving growth of the cancer cells.1
As a result of a collaboration with UNSW Sydney in 2016, Noxopharm already has drugs in its chemical library that are selective glutamate-inhibitors. This proprietary intellectual property centred on a search for a drug capable of protecting the brain from glutamate-associated brain damage following a stroke or severe concussion.
Noxopharm already has a number of potential lead candidates, which puts it well-placed to expedite the path to the clinic.
Dr Graham Kelly, Noxopharm Executive Chairman, said, “This is an exciting opportunity that we believe we lead the world on. It’s early stage with many questions yet to be answered, but if we are successful, then we see this approach as potentially having the same benefit as blocking the way sex hormones drive the growth of breast cancer and prostate cancer. If anti-hormone therapy can deliver very significant survival benefits with highly aggressive forms of breast cancer and prostate cancer, then we see no reason why blocking glutamate function cannot deliver the same benefit for patients with GBM.”
“A key challenge will be to limit a glutamate-blocking effect just to the tumour. A drug that blocks glutamate function in the brain generally would be far too toxic. Our compounds appear to work specifically where there is glutamate over-dose and have been well tolerated in animals to date. This is what we believe gives us a major competitive edge in what seems likely to be a major new area of drug development.”
The Company’s primary focus remains on Veyonda® and bringing it through the clinic and to market for the treatment of late-stage prostate cancer using its DARRT and LuPIN treatment regimens. The glutamate-inhibition program becomes the Company’s second pipeline drug program but will be secondary to the Veyonda® program.
References:
1. Venkataramani V et al (2019) Nature 573, 532-538.
2. Ye ZC, Sontheimer H. (1999) Cancer Res 59, 4383-4391.
About GBM
Glioblastoma multiforme (GBM) is the most common and most aggressive of the primary brain tumors. Patients with GBM present with symptoms such as headache and seizure often late in the disease when the tumour has become well-established and inoperable. As a result, the median survival is very short at about 12 months.
About Glutamate
Glutamate (glutamic acid) is a neurotransmitter that brain cells use to pass signals, including electrical impulses, between cells. It is important in learning and memory and is the dominant neurotransmitter in the brain and spinal cord. Glutamate works by increasing the entry of ions such as calcium into receiving nerve cells. Excessive amounts of glutamate lead to toxic amounts of calcium entering the cell, resulting in over-stimulation and death of healthy brain cells in a process known as excitotoxicity.
About Noxopharm
Noxopharm is a clinical-stage Australian drug development company with offices in Sydney and New York. The Company has a primary focus on the development of Veyonda® and is the major shareholder in Nyrada Inc, a spin-off company developing a pipeline of non-oncology drugs.
www.noxopharm.com
| Investor & Corporate Enquiries | |
| Media Contact Australia | Company Secretary: |
| Prue Kelly | David Franks |
| M: 0459 022 445 | T: +61 2 9299 9690 |
| E: Prue.Kelly@noxopharm.com | E: David.Franks@automicgroup.com.au |
| Media Contact USA: | |
| Frank de Maria | |
| Purposeful Communications | |
| T: +1 347 647 0284 | |
| E: frank.demaria@purposefulcommunications.com | |
Forward Looking Statements
This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.
